Certolizumab pegol (CZP) is a TNF-α inhibitor approved for the treatment of psoriatic arthritis in 38 countries, including many European countries and the USA. It is a pegylated humanized anti-TNF-α antigen-binding fragment, administered subcutaneously. As other TNF-α antibodies, CZP binds to and neutralizes both soluble and membrane TNF-α. In contrast to whole antibodies and etanercept, CZP do...

BACKGROUND Crohn's disease may be refractory to conventional treatments including corticosteroids and immunosuppressives. Recent studies suggest TNF-alpha blocking agents may be effective in maintaining remission in Crohn's disease. OBJECTIVES To conduct a systematic review of the evidence for the effectiveness of TNF-alpha blocking agents in the maintenance of remission in patients with Croh...

OBJECTIVES To evaluate the long-term efficacy and safety of certolizumab pegol (CZP) plus methotrexate treatment and to assess the efficacy of two CZP maintenance dosing schedules in Japanese rheumatoid arthritis (RA) patients with an inadequate response to methotrexate. METHODS J-RAPID double-blind patients were entered into an open-label extension (OLE) study. Patients withdrawn due to lack...

events were considered, reflecting the year 2015. All outcomes were discounted at 3.5% annually. Results: Regarding the AS subpopulation, the total treatment cost for IFX, ADA, CZP, ETA, GOL and CC was: € 67,736, € 38,914, € 38,721, € 38,290, € 35,338 and € 4,110; and the quality-adjusted life years (QALYs) were: 10.031, 9.882, 9.949, 9.933, 9.903 and 9.360, respectively. CZP dominated ADA and ...

OBJECTIVES An increased risk of tuberculosis (TB) has been reported in patients treated with TNF-α antagonists, an issue that has been highlighted in a WHO black box warning. This review aimed to assess the risk of TB in patients undergoing TNF-α antagonists treatment. METHODS A systematic literature search for randomised controlled trials (RCTs) was performed in MEDLINE, Embase and Cochrane ...

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of certolizumab pegol (CZP) for adults with active rheumatoid arthritis (RA) that have not responded adequately to treatment with conventional disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX), in accordance with the licensed indication, based...

This paper critically reviews the evidence for established (5-aminosalicylic acid [5-ASA] compounds, corticosteroids, immunomodulators, calcineurin inhibitors) and emerging novel therapies-including biological therapies-directed at cytokines (eg, infliximab, adalimumab, certolizumab pegol) and receptors (eg, visilizumab, abatacept) involved in T-cell activation, selective adhesion molecule bloc...